• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Atlantic Coastal Acquisition Corp. II filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year

    9/20/24 4:01:53 PM ET
    $ACAB
    Blank Checks
    Finance
    Get the next $ACAB alert in real time by email
    8-K
    false 0001893219 --12-31 0001893219 2024-09-19 2024-09-19 0001893219 acab:ClassAAndClassBCommonStockMember 2024-09-19 2024-09-19 0001893219 us-gaap:SeriesAPreferredStockMember 2024-09-19 2024-09-19 0001893219 us-gaap:WarrantMember 2024-09-19 2024-09-19

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    FORM 8-K

     

     

    CURRENT REPORT

    Pursuant to Section 13 or 15(d)

    of the Securities Exchange Act of 1934

    Date of Report (Date of earliest event reported): September 19, 2024

     

     

    ATLANTIC COASTAL ACQUISITION CORP. II

    (Exact name of registrant as specified in its charter)

     

     

     

    Delaware   001-41224   87-1013956
    (State or Other Jurisdiction
    of Incorporation)
      (Commission
    File Number)
      (I.R.S. Employer
    Identification No.)

     

    6 St Johns Lane, Floor 5

    New York, NY

      10013
    (Address of principal executive offices)   (Zip Code)

    (248) 890-7200

    (Registrant’s telephone number, including area code)

    N/A

    (Former name or former address, if changed since last report.)

     

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligations of the registrant under any of the following provisions (see General Instruction A.2. below):

     

    ☐

    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

     

    ☐

    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

     

    ☐

    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

     

    ☐

    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240-13e-4(c))

    Securities registered pursuant to Section 12(b) of the Act:

     

    Title of Each Class

     

    Trading
    Symbol(s)

     

    Name of Each Exchange
    on Which Registered

    Units, each consisting of one share of Series A common stock, $0.0001 par value, and one-half of one redeemable warrant   ACABU   The Nasdaq Stock Market LLC
    Shares of Series A common stock included as part of the units   ACAB   The Nasdaq Stock Market LLC
    Warrants included as part of the units, each whole warrant exercisable for one share of Series A common stock at an exercise price of $11.50   ACABW   The Nasdaq Stock Market LLC

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

    Emerging growth company ☒

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

     

     

     


    Item 5.03. Amendments to Articles of Incorporation or Bylaws.

    On September 19, 2024, at a special meeting of the stockholders of Atlantic Coastal Acquisition Corp. II, a Delaware corporation and a special purpose acquisition company ( the “Company”) whose securities are listed on Nasdaq (the “Special Meeting”), the stockholders approved a proposal to amend the Company’s amended and restated certificate of incorporation, as amended (the “Charter”), to extend the date by which the Company must (i) consummate a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination involving the Company and one or more businesses (a “Business Combination”), (ii) cease its operations if it fails to complete such Business Combination, and (iii) redeem or repurchase 100% of the Company’s Series A common stock included as part of the units sold in the Company’s initial public offering that was consummated on January 19, 2022 (the “Public Shares”), from September 19, 2024 (the “Original Termination Date”) to October 19, 2024 (the “Extended Date”), or such earlier date as determined by the Company’s board of directors (the “Board”), provided that the Company’s sponsor, Atlantic Coastal Acquisition Management II LLC, a Delaware limited liability company (the “Sponsor”), deposits into the trust account maintained for the benefit of the Company’s public stockholders $0.03 for each Public Share that is not redeemed in connection with the Special Meeting. If the Company has not consummated a Business Combination by the Extended Date, the Company may, without another stockholder vote, elect to extend the Extended Date on a monthly basis once (such monthly extension being hereinafter referred to as an “Additional Charter Extension Date”), by resolution of the Board, if requested by the Sponsor, and upon five days’ advance notice prior to the Extended Date, until November 19, 2024, or a total of up to two months after the Original Termination Date, unless the closing of a Business Combination shall have occurred prior thereto.

    The foregoing summary of the amendment to the Charter (the “Charter Amendment”) is not complete and is qualified by reference to the Charter Amendment attached hereto as Exhibit 3.1 which was filed with the Office of the Secretary of State of the State of Delaware on September 20, 2024.

    Item 5.07. Submission of Matters to a Vote of Security Holders.

    On September 19, 2024, the Company held a Special Meeting of Stockholders to vote upon the proposal to amend the Charter described in Item 5.03. An aggregate of 538,506 shares of the Company’s common stock, which represented a quorum of the outstanding common stock entitled to vote as of the record date of August 22, 2024, were represented in person or by proxy at the Special Meeting.

    The Company’s stockholders voted on the following proposal at the Special Meeting, which was approved:

    (1) Proposal No. 1 — The Charter Amendment Proposal — a proposal to amend the Charter to extend the date by which the Company must consummate a Business Combination (the “Charter Amendment Proposal”). The following is a tabulation of the votes with respect to this proposal, which was approved by the Company’s stockholders:

     

    For

     

    Against

     

    Abstain

     

    Broker Non-Votes

    517,796   20,710   0   N/A

    As of the close of business on September 19, 2024, stockholders holding a total of 126,122 public shares of Series A common stock exercised and did not reverse, their right to redeem their public shares in connection with the vote upon the Charter Amendment Proposal. As a result of the foregoing, those holders will receive a payment of approximately $11.27 per share redeemed.

    Item 9.01 Financial Statements and Exhibits.

    (d) Exhibits

     

    Exhibit No.

      

    Description

    3.1    Amendment No. 3 to the Amended and Restated Certificate of Incorporation.
    104    Cover Page Interactive Data File (embedded within the Inline XBRL document)


    SIGNATURE

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

    Dated: September 20, 2024

     

    ATLANTIC COASTAL ACQUISITION CORP. II
    By:  

    /s/ Shahraab Ahmad

      Shahraab Ahmad
      Chief Executive Officer
    Get the next $ACAB alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $ACAB

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $ACAB
    SEC Filings

    See more
    • SEC Form NT 10-Q filed by Atlantic Coastal Acquisition Corp. II

      NT 10-Q - Abpro Holdings, Inc. (0001893219) (Filer)

      11/15/24 4:05:03 PM ET
      $ACAB
      Blank Checks
      Finance
    • Atlantic Coastal Acquisition Corp. II filed SEC Form 8-K: Regulation FD Disclosure

      8-K - Abpro Holdings, Inc. (0001893219) (Filer)

      11/13/24 5:21:02 PM ET
      $ACAB
      Blank Checks
      Finance
    • SEC Form 25-NSE filed by Atlantic Coastal Acquisition Corp. II

      25-NSE - Atlantic Coastal Acquisition Corp. II (0001893219) (Subject)

      11/12/24 4:31:03 PM ET
      $ACAB
      Blank Checks
      Finance

    $ACAB
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • New insider Abpro Bio International, Inc. claimed ownership of 16,507,334 shares (SEC Form 3)

      3 - Abpro Holdings, Inc. (0001893219) (Issuer)

      11/18/24 9:00:34 PM ET
      $ACAB
      Blank Checks
      Finance
    • SEC Form 3 filed by new insider Mcdonald Ian

      3 - Abpro Holdings, Inc. (0001893219) (Issuer)

      11/18/24 8:52:41 PM ET
      $ACAB
      Blank Checks
      Finance
    • Co-CEO & Chairman Suk Jin Wook (Miles) was granted 91,900 shares (SEC Form 4)

      4 - Abpro Holdings, Inc. (0001893219) (Issuer)

      11/15/24 9:34:52 PM ET
      $ACAB
      Blank Checks
      Finance

    $ACAB
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Atlantic Coastal Acquisition Corp. II Receives Notification of Deficiency from Nasdaq Related to Delayed Quarterly Report on Form 10-Q

      NEW YORK, June 13, 2024 /PRNewswire/ -- Atlantic Coastal Acquisition Corp. II (NASDAQ:ACAB) (the "Company"), a special purpose acquisition company, announced that it had previously received written notification (the "Notice") from the Listing Qualifications Department of The Nasdaq Stock Market ("Nasdaq") on June 3, 2024 that, because the Company had not yet filed its Quarterly Report on Form 10-Q for the three month period ended March 31, 2024 (the "10-Q") with the Securities and Exchange Commission (the "SEC"), the Company was not in compliance with Nasdaq's continued listing requirements under Nasdaq Listing Rule 5250(c)(1). The Notice has no immediate effect on the listing of the Company

      6/13/24 4:15:00 PM ET
      $ACAB
      Blank Checks
      Finance
    • Abpro Announces Filing of Registration Statement on Form S-4 in Connection with Business Combination Agreement with Atlantic Coastal Acquisition Corp. II

      WOBURN, Mass. and NEW YORK, Jan. 22, 2024 (GLOBE NEWSWIRE) -- Abpro Corporation ("Abpro"), a biotech company with the mission of improving the lives of mankind facing severe and life-threatening diseases with next-generation antibody therapies, and Atlantic Coastal Acquisition Corp. II (NASDAQ:ACAB), a special purpose acquisition company ("Atlantic Coastal"), today announced the filing of a registration statement on Form S-4 (the "Registration Statement") with the U.S. Securities and Exchange Commission ("SEC") on January 19, 2024, which includes a preliminary proxy statement and prospectus in connection with its proposed business combination. Upon the closing of the proposed business

      1/22/24 8:00:00 AM ET
      $ACAB
      Blank Checks
      Finance
    • Abpro to Become Publicly Traded via Merger with Atlantic Coastal Acquisition Corp. II

      Abpro is a biotechnology company specializing in the development of next-generation antibody therapies intended to improve the lives of those with life-threatening diseases. The transaction values Abpro at $725 million and will help advance Abpro's drug pipeline to clinical trials. Abpro Corporation ("Abpro"), a biotechnology company with the mission of improving the lives of those facing severe and life-threatening diseases with next-generation antibody therapies, and Atlantic Coastal Acquisition Corp. II (NASDAQ:ACAB), a special purpose acquisition corporation ("Atlantic Costal"), today announced a term sheet to enter into a definitive business combination, which was entered into o

      9/21/23 4:00:00 PM ET
      $ACAB
      Blank Checks
      Finance

    $ACAB
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by Atlantic Coastal Acquisition Corp. II (Amendment)

      SC 13G/A - Atlantic Coastal Acquisition Corp. II (0001893219) (Subject)

      2/7/24 1:53:24 PM ET
      $ACAB
      Blank Checks
      Finance
    • SEC Form SC 13G/A filed by Atlantic Coastal Acquisition Corp. II (Amendment)

      SC 13G/A - Atlantic Coastal Acquisition Corp. II (0001893219) (Subject)

      1/19/24 4:17:41 PM ET
      $ACAB
      Blank Checks
      Finance
    • SEC Form SC 13D filed by Atlantic Coastal Acquisition Corp. II

      SC 13D - Atlantic Coastal Acquisition Corp. II (0001893219) (Subject)

      4/20/23 6:01:50 AM ET
      $ACAB
      Blank Checks
      Finance